{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:31:35Z","timestamp":1780317095715,"version":"3.54.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Aberrant glycosylation, catalyzed by the specific glycosyltransferase, is one of the dominant features of cancers. Among the glycosyltransferase subfamilies, sialyltransferases (SiaTs) are an essential part which has close linkages with tumor-associated events, such as tumor growth, metastasis and angiogenesis. Considering the relationship between SiaTs and cancer, the current study attempted to establish an effective prognostic model with SiaTs-related genes (SRGs) to predict patients\u2019 outcome and therapeutic responsiveness of bladder cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>RNA-seq data, clinical information and genomic mutation data were downloaded (TCGA-BLCA and GSE13507 datasets). The comprehensive landscape of the 20 SiaTs was analyzed, and the differentially expressed SiaTs-related genes were screened with \u201cDESeq2\u201d R package. ConsensusClusterPlus was applied for clustering, following with survival analysis with Kaplan\u2013Meier curve. The overall survival related SRGs were determined with univariate Cox proportional hazards regression analysis, and the least absolute shrinkage and selection operator (LASSO) regression analysis was performed to generate a SRGs-related prognostic model. The predictive value was estimated with Kaplan\u2013Meier plot and the receiver operating characteristic (ROC) curve, which was further validated with the constructed nomogram and decision curve.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In bladder cancer tissues, 17 out of the\u00a020 SiaTs were differentially expressed with CNV changes and somatic mutations. Two SiaTs_Clusters were determined based on the expression of the\u00a020 SiaTs, and two gene_Clusters were identified based on the expression of differentially expressed genes between SiaTs_Clusters. The SRGs-related prognostic model was generated with 7 key genes (CD109, TEAD4, FN1, TM4SF1, CDCA7L, ATOH8 and GZMA), and the accuracy for outcome prediction was validated with ROC curve and a constructed nomogram. The SRGs-related prognostic signature could separate patients into high- and low-risk group, where the high-risk group showed poorer outcome, more abundant immune infiltration, and higher expression of immune checkpoint genes. In addition, the risk score derived from the SRGs-related prognostic model could be utilized as a predictor to evaluate the responsiveness of patients to the medical therapies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The SRGs-related prognostic signature could potentially aid in the prediction of the survival outcome and therapy response for patients with bladder cancer, contributing to the development of personalized treatment and appropriate medical decisions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-023-01496-7","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T07:02:02Z","timestamp":1700031722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Penglong","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"issue":"8","key":"1496_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41585-022-00611-3","volume":"19","author":"A Martin","year":"2022","unstructured":"Martin A, Woolbright BL, Umar S, Ingersoll MA, Taylor JA 3rd. Bladder cancer, inflammageing and microbiomes. Nat Rev Urol. 2022;19(8):495\u2013509.","journal-title":"Nat Rev Urol"},{"issue":"19","key":"1496_CR2","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.3390\/cancers15194886","volume":"15","author":"B Rani","year":"2023","unstructured":"Rani B, Ignatz-Hoover JJ, Rana PS, Driscoll JJ. Current and emerging strategies to treat urothelial carcinoma. Cancers (Basel). 2023;15(19):4886.","journal-title":"Cancers (Basel)"},{"issue":"13","key":"1496_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.904536","volume":"3","author":"J Yao","year":"2022","unstructured":"Yao J, Liu Y, Yang J, Li M, Li S, Zhang B, et al. Single-Cell sequencing reveals that DBI is the key gene and potential therapeutic target in quiescent bladder cancer stem cells. Front Genet. 2022;3(13): 904536.","journal-title":"Front Genet"},{"issue":"12","key":"1496_CR4","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.7150\/ijbs.63125","volume":"17","author":"W Lin","year":"2021","unstructured":"Lin W, Sun J, Sadahira T, Xu N, Wada K, Liu C, et al. Discovery and validation of nitroxoline as a novel STAT3 inhibitor in drug-resistant urothelial bladder cancer. Int J Biol Sci. 2021;17(12):3255\u201367.","journal-title":"Int J Biol Sci"},{"issue":"6","key":"1496_CR5","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/cancers12061417","volume":"12","author":"YG Roh","year":"2020","unstructured":"Roh YG, Mun JY, Kim SK, Park W, Jeong MS, Kim TN, et al. Fanconi anemia pathway activation by FOXM1 is critical to bladder cancer recurrence and anticancer drug resistance. Cancers (Basel). 2020;12(6):1417.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1496_CR6","doi-asserted-by":"publisher","first-page":"2124691","DOI":"10.1080\/2162402X.2022.2124691","volume":"11","author":"J Huang","year":"2022","unstructured":"Huang J, Su R, Chen Z, Jiang S, Chen M, Yuan Y, et al. The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy. Oncoimmunology. 2022;11(1):2124691.","journal-title":"Oncoimmunology"},{"issue":"9","key":"1496_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.ccell.2022.08.010","volume":"40","author":"M Wang","year":"2022","unstructured":"Wang M, Chen X, Tan P, Wang Y, Pan X, Lin T, et al. Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer. Cancer Cell. 2022;40(9):1044\u201359.","journal-title":"Cancer Cell"},{"issue":"6","key":"1496_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188806","volume":"1877","author":"J Zhang","year":"2022","unstructured":"Zhang J, Xun M, Li C, Chen Y. The O-GlcNAcylation and its promotion to hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer. 2022;1877(6): 188806.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"549","key":"1496_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215902","volume":"28","author":"S Yang","year":"2022","unstructured":"Yang S, Cui M, Liu Q, Liao Q. Glycosylation of immunoglobin G in tumors: function, regulation and clinical implications. Cancer Lett. 2022;28(549): 215902.","journal-title":"Cancer Lett"},{"issue":"23\u201324","key":"1496_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.202200156","volume":"22","author":"J Li","year":"2022","unstructured":"Li J, Guo B, Zhang W, Yue S, Huang S, Gao S, et al. Recent advances in demystifying O-glycosylation in health and disease. Proteomics. 2022;22(23\u201324): e2200156.","journal-title":"Proteomics"},{"issue":"11","key":"1496_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102546","volume":"298","author":"C Marques","year":"2022","unstructured":"Marques C, Po\u00e7as J, Gomes C, Faria-Ramos I, Reis CA, Viv\u00e8s RR, et al. Glycosyltransferases EXTL2 and EXTL3 cellular balance dictates Heparan Sulfate biosynthesis and shapes gastric cancer cell motility and invasion. J Biol Chem. 2022;298(11): 102546.","journal-title":"J Biol Chem"},{"issue":"13","key":"1496_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.979605","volume":"12","author":"J Liu","year":"2022","unstructured":"Liu J, Li M, Wu J, Qi Q, Li Y, Wang S, et al. Identification of ST3GAL5 as a prognostic biomarker correlating with CD8+ T cell exhaustion in clear cell renal cell carcinoma. Front Immunol. 2022;12(13): 979605.","journal-title":"Front Immunol"},{"issue":"10","key":"1496_CR13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41589-022-01085-5","volume":"18","author":"Q Zhu","year":"2022","unstructured":"Zhu Q, Zhou H, Wu L, Lai Z, Geng D, Yang W, et al. O-GlcNAcylation promotes pancreatic tumor growth by regulating malate dehydrogenase 1. Nat Chem Biol. 2022;18(10):1087\u201395.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"1496_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41417-022-00530-w","volume":"30","author":"Q Wang","year":"2023","unstructured":"Wang Q, Liao C, Tan Z, Li X, Guan X, Li H, et al. FUT6 inhibits the proliferation, migration, invasion, and EGF-induced EMT of head and neck squamous cell carcinoma (HNSCC) by regulating EGFR\/ERK\/STAT signaling pathway. Cancer Gene Ther. 2023;30(1):182\u201391.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"1496_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s11658-022-00378-w","volume":"27","author":"Q Hu","year":"2022","unstructured":"Hu Q, Tian T, Leng Y, Tang Y, Chen S, Lv Y, et al. The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer. Cell Mol Biol Lett. 2022;27(1):71.","journal-title":"Cell Mol Biol Lett"},{"issue":"12","key":"1496_CR16","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s41419-021-04416-x","volume":"12","author":"S Lin","year":"2021","unstructured":"Lin S, Zhou L, Dong Y, Yang Q, Yang Q, Jin H, et al. Alpha-(1,6)- fucosyltransferase (FUT8) affects the survival strategy of osteosarcoma by remodeling TNF\/NF-\u03baB2 signaling. Cell Death Dis. 2021;12(12):1124.","journal-title":"Cell Death Dis"},{"issue":"8","key":"1496_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s43018-022-00405-x","volume":"3","author":"NW Mabe","year":"2022","unstructured":"Mabe NW, Huang M, Dalton GN, Alexe G, Schaefer DA, Geraghty AC, et al. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1. Nat Cancer. 2022;3(8):976\u201393.","journal-title":"Nat Cancer"},{"issue":"2","key":"1496_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1158\/2326-6066.CIR-19-0514","volume":"8","author":"M Kvorjak","year":"2020","unstructured":"Kvorjak M, Ahmed Y, Miller ML, Sriram R, Coronnello C, Hashash JG, et al. Cross-talk between colon cells and macrophages increases ST6GALNAC1 and MUC1-sTn expression in ulcerative colitis and colitis-associated colon cancer. Cancer Immunol Res. 2020;8(2):167\u201378.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1496_CR19","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1038\/s41467-020-19575-2","volume":"11","author":"S Pietrobono","year":"2020","unstructured":"Pietrobono S, Anichini G, Sala C, Manetti F, Almada LL, Pepe S, et al. ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL. Nat Commun. 2020;11(1):5865.","journal-title":"Nat Commun"},{"issue":"17","key":"1496_CR20","doi-asserted-by":"publisher","first-page":"6239","DOI":"10.3390\/ijms21176239","volume":"21","author":"PE Guerrero","year":"2020","unstructured":"Guerrero PE, Mir\u00f3 L, Wong BS, Massaguer A, Mart\u00ednez-Bosch N, Llorens R, et al. Knockdown of \u03b12,3-sialyltransferases impairs pancreatic cancer cell migration, invasion and e-selectin-dependent adhesion. Int J Mol Sci. 2020;21(17):6239.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1496_CR21","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/s41417-022-00485-y","volume":"29","author":"NC Hait","year":"2022","unstructured":"Hait NC, Maiti A, Wu R, Andersen VL, Hsu CC, Wu Y, et al. Extracellular sialyltransferase st6gal1 in breast tumor cell growth and invasiveness. Cancer Gene Ther. 2022;29(11):1662\u201375.","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"1496_CR22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.neo.2019.03.009","volume":"21","author":"J Hao","year":"2019","unstructured":"Hao J, Zeltz C, Pintilie M, Li Q, Sakashita S, Wang T, et al. Characterization of distinct populations of carcinoma-associated fibroblasts from non-small cell lung carcinoma reveals a role for ST8SIA2 in cancer cell invasion. Neoplasia. 2019;21(5):482\u201393.","journal-title":"Neoplasia"},{"issue":"15","key":"1496_CR23","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.2147\/JIR.S385491","volume":"10","author":"R Liu","year":"2022","unstructured":"Liu R, Cao X, Liang Y, Li X, Jin Q, Li Y, et al. Downregulation of ST6GAL1 promotes liver inflammation and predicts adverse prognosis in hepatocellular carcinoma. J Inflamm Res. 2022;10(15):5801\u201314.","journal-title":"J Inflamm Res"},{"issue":"19","key":"1496_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12935-019-0780-7","volume":"5","author":"WY Wang","year":"2019","unstructured":"Wang WY, Cao YX, Zhou X, Wei B, Zhan L, Sun SY. Stimulative role of ST6GALNAC1 in proliferation, migration and invasion of ovarian cancer stem cells via the Akt signaling pathway. Cancer Cell Int. 2019;5(19):86.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1496_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/path.6152","volume":"261","author":"E Scott","year":"2023","unstructured":"Scott E, Archer Goode E, Garnham R, Hodgson K, Orozco-Moreno M, Turner H, et al. ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression. J Pathol. 2023;261(1):71\u201384.","journal-title":"J Pathol"},{"issue":"4","key":"1496_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/14737159.2023.2195553","volume":"23","author":"NA di Meo","year":"2023","unstructured":"di Meo NA, Lasorsa F, Rutigliano M, Milella M, Ferro M, Battaglia M, et al. The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery. Expert Rev Mol Diagn. 2023;23(4):297\u2013313.","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"1496_CR27","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/ijms24020910","volume":"24","author":"F Lasorsa","year":"2023","unstructured":"Lasorsa F, di Meo NA, Rutigliano M, Ferro M, Terracciano D, Tataru OS, et al. Emerging hallmarks of metabolic reprogramming in prostate cancer. Int J Mol Sci. 2023;24(2):910.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1496_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/14737159.2019.1604223","volume":"19","author":"G Lucarelli","year":"2019","unstructured":"Lucarelli G, Loizzo D, Ferro M, Rutigliano M, Vartolomei MD, Cantiello F, et al. Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update. Expert Rev Mol Diagn. 2019;19(5):377\u201387.","journal-title":"Expert Rev Mol Diagn"},{"issue":"22","key":"1496_CR29","doi-asserted-by":"publisher","first-page":"14360","DOI":"10.3390\/ijms232214360","volume":"23","author":"NA di Meo","year":"2022","unstructured":"di Meo NA, Lasorsa F, Rutigliano M, Loizzo D, Ferro M, Stella A, et al. Renal cell carcinoma as a metabolic disease: an update on main pathways, potential biomarkers, and therapeutic targets. Int J Mol Sci. 2022;23(22):14360.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1496_CR30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/14737159.2019.1607729","volume":"19","author":"G Lucarelli","year":"2019","unstructured":"Lucarelli G, Loizzo D, Franzin R, Battaglia S, Ferro M, Cantiello F, et al. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019;19(5):397\u2013407.","journal-title":"Expert Rev Mol Diagn"},{"issue":"8","key":"1496_CR31","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.3390\/ijms23084173","volume":"23","author":"NA di Meo","year":"2022","unstructured":"di Meo NA, Loizzo D, Pandolfo SD, Autorino R, Ferro M, Porta C, et al. Metabolomic approaches for detection and identification of biomarkers and altered pathways in bladder cancer. Int J Mol Sci. 2022;23(8):4173.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1496_CR32","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/cam4.1109","volume":"6","author":"D Sahu","year":"2017","unstructured":"Sahu D, Lotan Y, Wittmann B, Neri B, Hansel DE. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer. Cancer Med. 2017;6(9):2106\u201320.","journal-title":"Cancer Med"},{"issue":"13","key":"1496_CR33","doi-asserted-by":"publisher","first-page":"10846","DOI":"10.3390\/ijms241310846","volume":"24","author":"A Aveta","year":"2023","unstructured":"Aveta A, Cilio S, Contieri R, Spena G, Napolitano L, Manfredi C, et al. Urinary MicroRNAs as biomarkers of urological cancers: a systematic review. Int J Mol Sci. 2023;24(13):10846.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1496_CR34","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.clgc.2023.05.017","volume":"21","author":"M Ferro","year":"2023","unstructured":"Ferro M, Crocetto F, Tataru S, Barone B, Dolce P, Lucarelli G, et al. Predictors of efficacy of immune checkpoint inhibitors in patients with advanced urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer. 2023;21(5):574\u201383.","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"1496_CR35","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.3390\/cancers14102545","volume":"14","author":"B Barone","year":"2022","unstructured":"Barone B, Calogero A, Scafuri L, Ferro M, Lucarelli G, Di Zazzo E, et al. Immune checkpoint inhibitors as a neoadjuvant\/adjuvant treatment of muscle-invasive bladder cancer: a systematic review. Cancers (Basel). 2022;14(10):2545.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1496_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/jpm11030237","volume":"11","author":"M Ferro","year":"2021","unstructured":"Ferro M, La Civita E, Liotti A, Cennamo M, Tortora F, Buonerba C, et al. Liquid biopsy biomarkers in urine: a route towards molecular diagnosis and personalized medicine of bladder cancer. J Pers Med. 2021;11(3):237.","journal-title":"J Pers Med"},{"issue":"13","key":"1496_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.963877","volume":"8","author":"S Pan","year":"2022","unstructured":"Pan S, Li S, Zhan Y, Chen X, Sun M, Liu X, et al. Immune status for monitoring and treatment of bladder cancer. Front Immunol. 2022;8(13): 963877.","journal-title":"Front Immunol"},{"issue":"18","key":"1496_CR38","doi-asserted-by":"publisher","first-page":"10496","DOI":"10.3390\/ijms231810496","volume":"23","author":"PK Biswas","year":"2022","unstructured":"Biswas PK, Kwak Y, Kim A, Seok J, Kwak HJ, Lee M, et al. TTYH3 modulates bladder cancer proliferation and metastasis via FGFR1\/H-Ras\/A-Raf\/MEK\/ERK pathway. Int J Mol Sci. 2022;23(18):10496.","journal-title":"Int J Mol Sci"},{"issue":"26","key":"1496_CR39","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.omto.2022.08.004","volume":"5","author":"PM Chow","year":"2022","unstructured":"Chow PM, Dong JR, Chang YW, Kuo KL, Lin WC, Liu SH, et al. The UCHL5 inhibitor b-AP15 overcomes cisplatin resistance via suppression of cancer stemness in urothelial carcinoma. Mol Ther Oncolytics. 2022;5(26):387\u201398.","journal-title":"Mol Ther Oncolytics"},{"issue":"11","key":"1496_CR40","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/iub.2562","volume":"73","author":"L Wang","year":"2021","unstructured":"Wang L, Chen X, Wang L, Wang S, Li W, Liu Y, et al. Knockdown of ST6Gal-I expression in human hepatocellular carcinoma cells inhibits their exosome-mediated proliferation- and migration-promoting effects. IUBMB Life. 2021;73(11):1378\u201391.","journal-title":"IUBMB Life"},{"issue":"12","key":"1496_CR41","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-18-0399","volume":"17","author":"K Nguyen","year":"2018","unstructured":"Nguyen K, Yan Y, Yuan B, Dasgupta A, Sun J, Mu H, et al. ST8SIA1 regulates tumor growth and metastasis in TNBC by activating the FAK-AKT-mTOR signaling pathway. Mol Cancer Ther. 2018;17(12):2689\u2013701.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"1496_CR42","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1002\/ijc.31891","volume":"144","author":"HL Yeo","year":"2019","unstructured":"Yeo HL, Fan TC, Lin RJ, Yu JC, Liao GS, Chen ES, et al. Sialylation of vasorin by ST3Gal1 facilitates TGF-\u03b21-mediated tumor angiogenesis and progression. Int J Cancer. 2019;144(8):1996\u20132007.","journal-title":"Int J Cancer"},{"issue":"6","key":"1496_CR43","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/onc.2014.7","volume":"34","author":"H Ma","year":"2015","unstructured":"Ma H, Zhou H, Song X, Shi S, Zhang J, Jia L. Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia. Oncogene. 2015;34(6):726\u201340.","journal-title":"Oncogene"},{"issue":"18","key":"1496_CR44","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12935-018-0675-z","volume":"12","author":"W Zhang","year":"2018","unstructured":"Zhang W, Li J, Wu Y, Ge H, Song Y, Wang D, et al. TEAD4 overexpression promotes epithelial-mesenchymal transition and associates with aggressiveness and adverse prognosis in head neck squamous cell carcinoma. Cancer Cell Int. 2018;12(18):178.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"1496_CR45","doi-asserted-by":"publisher","first-page":"1008075","DOI":"10.3389\/fchem.2022.1008075","volume":"15","author":"M Cozzaglio","year":"2022","unstructured":"Cozzaglio M, Ceschi S, Groaz E, Sturlese M, Sissi C. G-quadruplexes formation within the promoter of TEAD4 oncogene and their interaction with Vimentin. Front Chem. 2022;15(10):1008075.","journal-title":"Front Chem"},{"issue":"4","key":"1496_CR46","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/jgh.15779","volume":"37","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Bai J, Cheng R, Zhang D, Qiu Z, Liu T, et al. TAZ promotes vasculogenic mimicry in gastric cancer through the upregulation of TEAD4. J Gastroenterol Hepatol. 2022;37(4):714\u201326.","journal-title":"J Gastroenterol Hepatol"},{"issue":"17","key":"1496_CR47","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1158\/0008-5472.CAN-19-0012","volume":"79","author":"L He","year":"2019","unstructured":"He L, Yuan L, Sun Y, Wang P, Zhang H, Feng X, et al. Glucocorticoid receptor signaling activates TEAD4 to promote breast cancer progression. Cancer Res. 2019;79(17):4399\u2013411.","journal-title":"Cancer Res"},{"issue":"1","key":"1496_CR48","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13046-022-02377-3","volume":"41","author":"M Chi","year":"2022","unstructured":"Chi M, Liu J, Mei C, Shi Y, Liu N, Jiang X, et al. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K\/AKT pathway in bladder cancer. J Exp Clin Cancer Res. 2022;41(1):175.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"1496_CR49","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1089\/dna.2021.0164","volume":"40","author":"J Wang","year":"2021","unstructured":"Wang J, Shen C, Zhang J, Zhang Y, Liang Z, Niu H, et al. TEAD4 is an immune regulating-related prognostic biomarker for bladder cancer and possesses generalization value in pan-cancer. DNA Cell Biol. 2021;40(6):798\u2013810.","journal-title":"DNA Cell Biol"},{"issue":"1","key":"1496_CR50","first-page":"136","volume":"11","author":"SSK Divvela","year":"2022","unstructured":"Divvela SSK, Saberi D, Brand-Saberi B. Atoh8 in development and disease. Biology (Basel). 2022;11(1):136.","journal-title":"Biology (Basel)"},{"issue":"1","key":"1496_CR51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jmcb\/mjaa050","volume":"13","author":"M Xu","year":"2021","unstructured":"Xu M, Huang S, Dong X, Chen Y, Li M, Shi W, et al. A novel isoform of ATOH8 promotes the metastasis of breast cancer by regulating RhoC. J Mol Cell Biol. 2021;13(1):59\u201371.","journal-title":"J Mol Cell Biol"},{"issue":"4","key":"1496_CR52","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1053\/j.gastro.2015.06.010","volume":"149","author":"Y Song","year":"2015","unstructured":"Song Y, Pan G, Chen L, Ma S, Zeng T, Man Chan TH, et al. Loss of ATOH8 increases stem cell features of hepatocellular carcinoma cells. Gastroenterology. 2015;149(4):1068\u201381.","journal-title":"Gastroenterology"},{"issue":"13","key":"1496_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.901518","volume":"7","author":"X Hu","year":"2022","unstructured":"Hu X, Yang Y, Wang Y, Ren S, Li X. Identifying an immune-related gene ST8SIA1 as a novel target in patients with clear-cell renal cell carcinoma. Front Pharmacol. 2022;7(13): 901518.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1496_CR54","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3390\/jpm12030401","volume":"12","author":"CY Ko","year":"2022","unstructured":"Ko CY, Chu TH, Hsu CC, Chen HP, Huang SC, Chang CL, et al. Bioinformatics analyses identify the therapeutic potential of ST8SIA6 for colon cancer. J Pers Med. 2022;12(3):401.","journal-title":"J Pers Med"},{"issue":"13","key":"1496_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.827457","volume":"21","author":"M Yang","year":"2022","unstructured":"Yang M, Wang B, Hou W, Yu H, Zhou B, Zhong W, et al. Negative effects of stromal neutrophils on T cells reduce survival in resectable urothelial carcinoma of the bladder. Front Immunol. 2022;21(13): 827457.","journal-title":"Front Immunol"},{"issue":"18","key":"1496_CR56","doi-asserted-by":"publisher","first-page":"7364","DOI":"10.18632\/aging.204200","volume":"14","author":"Z Tang","year":"2022","unstructured":"Tang Z, Tang C, Sun C, Ying X, Shen R. M1 macrophage-derived exosomes synergistically enhance the anti- bladder cancer effect of gemcitabine. Aging (Albany NY). 2022;14(18):7364\u201377.","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"1496_CR57","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ijrobp.2022.06.054","volume":"114","author":"Y Chiang","year":"2022","unstructured":"Chiang Y, Tsai YC, Wang CC, Hsueh FJ, Huang CY, Chung SD, et al. Tumor-Derived C-C motif ligand 2 induces the recruitment and polarization of tumor-associated macrophages and increases the metastatic potential of bladder cancer cells in the postirradiated microenvironment. Int J Radiat Oncol Biol Phys. 2022;114(2):321\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1496_CR58","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1245\/s10434-021-11155-y","volume":"29","author":"S Jin","year":"2022","unstructured":"Jin S, Zeng H, Liu Z, Jin K, Liu C, Yan S, et al. Stromal tumor-associated macrophage infiltration predicts poor clinical outcomes in muscle-invasive bladder cancer patients. Ann Surg Oncol. 2022;29(4):2495\u2013503.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"1496_CR59","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1474317","volume":"7","author":"Z Liu","year":"2018","unstructured":"Liu Z, Zhu Y, Xu L, Zhang J, Xie H, Fu H, et al. Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer. Oncoimmunology. 2018;7(9): e1474317.","journal-title":"Oncoimmunology"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01496-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01496-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01496-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T08:04:45Z","timestamp":1700035485000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01496-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1496"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01496-7","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data are from public databases and an ethics approval is waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"515"}}